These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15744818)

  • 1. Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts.
    Cho ES; Yu JH; Kim MS; Yim M
    Yonsei Med J; 2005 Feb; 46(1):149-54. PubMed ID: 15744818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts.
    Park H; Young Lee S; Lee DS; Yim M
    Biochem Biophys Res Commun; 2007 Mar; 354(1):178-83. PubMed ID: 17222389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells.
    Cho ES; Yu JH; Kim MS; Yim M
    Arch Pharm Res; 2004 Dec; 27(12):1258-62. PubMed ID: 15646801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
    Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
    MacKenzie SJ; Houslay MD
    Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability.
    Park H; Yim M
    Arch Pharm Res; 2007 Apr; 30(4):486-92. PubMed ID: 17489366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.
    Chen TC; Wadsten P; Su S; Rawlinson N; Hofman FM; Hill CK; Schönthal AH
    Cancer Biol Ther; 2002; 1(3):268-76. PubMed ID: 12432276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways.
    Takami M; Cho ES; Lee SY; Kamijo R; Yim M
    FEBS Lett; 2005 Jan; 579(3):832-8. PubMed ID: 15670856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice.
    Thompson BE; Sachs BD; Kantak KM; Cherry JA
    Eur J Neurosci; 2004 May; 19(9):2561-8. PubMed ID: 15128409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
    Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
    J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
    Jimenez JL; Punzón C; Navarro J; Muñoz-Fernández MA; Fresno M
    J Pharmacol Exp Ther; 2001 Nov; 299(2):753-9. PubMed ID: 11602691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of the involvement of protein kinase A in D2 dopamine receptor antagonist-induced immediate early gene expression.
    Adams AC; Keefe KA
    J Neurochem; 2001 Apr; 77(1):326-35. PubMed ID: 11279288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
    Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
    Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
    Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
    Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
    Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
    Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
    Makhay MM; Houslay MD; O'Donnell JM
    Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function.
    Miller AH; Vogt GJ; Pearce BD
    Neuropsychopharmacology; 2002 Dec; 27(6):939-48. PubMed ID: 12464451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
    Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
    Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.